すべての臨床医が知っておきたいIBDの診かた

出版社： 羊土社
著者：
発行日： 2023-10-15
分野： 臨床医学：内科  >  消化器一般
ISBN： 9784758110808
電子書籍版： 2023-10-15 （第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：4～8営業日

5,500 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

5,500 円(税込)

購入する

商品紹介

薬剤の種類が多い，病態が多様など悩ましいIBD．疑うべき症状から，病態・疾患活動性と結びつけた治療の考え方・実際の処方まで最新知見をふまえ解説．合併症や高齢・小児・がん患者等でおさえるべきこともわかる

目次

  • 第1章　IBDの知っておくべき基礎知識
    　１）IBDとは～どのような疾患なのか？
    　２）歴史～いつ報告されたのか？
    　３）疫学～海外・日本の動向とは？
    　column
    　　◆ Crohn先生も驚いている！？

    第2章　IBDの病因・病態
    　１）IBD発症に関連する因子～遺伝的素因・環境因子・腸内細菌の重要性
    　２）免疫異常がもたらす複雑な病態～腸管上皮細胞・免疫細胞・サイトカインからIBDをみる
    　column
    　　◆ FMT 治療はIBD にも有効？
    　　◆ 細菌の分類と学名についておさらいしよう
    　　◆ Tfh細胞とは
    　　◆ pTreg のなかにも種類がある
    　　◆ IBD 治療薬によるB 細胞への影響はある？

    第3章　IBDの診断
    　１）どのような場合にIBDを疑って診断を進めていくか？
    　２）診断基準と鑑別～厚生労働省診断基準
    　column
    　　◆ IBD の情報を入手しよう

    第4章　IBDにおける画像検査
    　１）画像検査をどのように活用するか？
    　２）各検査の特徴

    第5章　IBDの治療
    　§１　治療の基本
    　　１）治療概念の変遷
    　　２）UC治療の基本アルゴリズム
    　　３）CD治療の基本アルゴリズム
    　　４）専門施設へ紹介すべきタイミング
    　§２　内科治療と副作用
    　　１）5-ASA製剤
    　　２）ステロイド
    　　３）チオプリン製剤（免疫調節薬）
    　　４）カルシニューリン阻害薬（免疫抑制薬）
    　　５）血球成分除去療法
    　　６）抗TNF-α抗体製剤（生物学的製剤）
    　　７）抗IL-12/23p40抗体製剤（生物学的製剤）
    　　８）インテグリン阻害薬（生物学的製剤）
    　　９）JAK阻害薬（低分子化合物）
    　　10）抗IL-23p19抗体製剤（生物学的製剤）
    　§３　最新治療
    　　１）GLP-2 アナログ（テデュクルチド）
    　　２） MSC療法
    　§４　IBDの外科治療
    　　１）UCの外科治療
    　　２）CDの外科治療
    　column
    　　◆ アドヒアランス向上をめざした投与法における課題
    　　◆ 5-ASAのdrug delivery systemに少しふれてみよう
    　　◆ 新規ステロイドが使用可能に！
    　　◆ TPMT活性ってなに？
    　　◆ タクロリムスはmade in Japan
    　　◆ CAPで治療の選択肢が広がる！
    　　◆ 抗TNF-α抗体製剤をどう選択する?
    　　◆ S1P 受容体モジュレーター
    　　◆ 脂肪組織由来幹細胞は移植できる

    第6章　IBDの合併症
    　１）知っておくべき腸管外症状
    　２）関節炎
    　３）感染症
    　４）血栓症
    　５）炎症性発がん
    　６）骨粗鬆症，サルコペニア
    　７）原発性硬化性胆管炎（PSC）
    　８）皮膚病変
    　column
    　　◆ CMV感染診断は難しい？
    　　◆ GDH抗原検査とは？
    　　◆ CD関連直腸肛門管がん
    　　◆ CD関連小腸がん
    　　◆ dysplasiaの診断基準について，勉強しよう

    第7章　IBDのspecial situation
    　１）高齢IBD患者
    　２）小児IBD患者の治療・管理
    　３）がん患者のIBD管理
    　４）IBD患者における妊娠
    　５）IBDとSARS-CoV-2感染
    　column
    　　◆ 日本IBD COVID-19患者登録コホート（J-COSMOS）の最終解析
    　Advanced
    　　これからのIBD治療に向けて～OmicsパネルのIBD病態解明・治療への応用
    　column
    　　◆ AIを用いた粘膜治癒評価

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 IBDの知っておくべき基礎知識

P.13 掲載の参考文献
1) Wilks S:Morbid appearances in the intestine of Miss Bankes. London Med Gazette, 2:264-265, 1859
 
2) 稲田龍吉:重症潰瘍性大腸炎について. 日本消化器病学会雑誌, 27:625-638, 1928
 
3) Weir RF:A new use for the useless appendix in surgical treatment of obstinate colitis. Med Rec. 62:201-202, 1902
 
4) 「The Seats and Causes of Diseases」[Book III, Letter XXXI, Article 2](Morgagni GB)pp.64-66, Hafner Publishing, 1960
 
5) Dalziel TK:Chronic interstitial enteritis. Br Med J, 2:1068-1070, 1913
 
6) Crohn BB, et al:Regional ileitis:a pathologic and clinical entity. JAMA, 99:1323-1329, 1932
 
7) Mulder DJ, et al:A tale of two diseases:the history of inflammatory bowel disease. J Crohns Colitis, 8:341-348, 2014
PubMed
P.16 掲載の参考文献
1) Crafts, N:Productivity growth in the industrial revolution:A new growth accounting perspective. J Econom History, 64:521-535, 2004
 
2) Bach JF:The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med, 347:911-920, 2002
PubMed
3) Kirsner JB:Historical aspects of inflammatory bowel disease. J Clin Gastroenterol, 10:286-297, 1988
PubMed
4) Molodecky NA, et al:Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology, 142:46-54.e42;quiz e30, 2012
 
5) Benchimol EI, et al:Increasing incidence of paediatric inflammatory bowel disease in Ontario, Canada:evidence from health administrative data. Gut, 58:1490-1497, 2009
PubMed
6) Benchimol EI, et al:Changing age demographics of inflammatory bowel disease in Ontario, Canada:a population-based cohort study of epidemiology trends. Inflamm Bowel Dis, 20:1761-1769, 2014
 
7) Burisch J, et al:East-West gradient in the incidence of inflammatory bowel disease in Europe:the ECCO-EpiCom inception cohort. Gut, 63:588-597, 2014
PubMed
8) 厚生労働省:難病情報センター ホームページ http://www.nanbyou.or.jp(2023年7月閲覧)
 
9) Murakami Y, et al:Estimated prevalence of ulcerative colitis and Crohn's disease in Japan in 2014:an analysis of a nationwide survey. J Gastroenterol, 54:1070-1077, 2019
PubMed
10) Park SJ, et al:Clinical characteristics and treatment of inflammatory bowel disease:a comparison of Eastern and Western perspectives. World J Gastroenterol, 20:11525-11537, 2014
PubMed
11) Ng SC:Emerging leadership lecture:Inflammatory bowel disease in Asia:emergence of a "Western" disease. J Gastroenterol Hepatol, 30:440-445, 2015
 
12) Ng SC, et al:Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn's and colitis epidemiology study. Gastroenterology, 145:158-165.e2, 2013
 
13) Sood A, et al:Incidence and prevalence of ulcerative colitis in Punjab, North India. Gut, 52:1587-1590, 2003
PubMed
14) Tozun N, et al:Clinical characteristics of inflammatory bowel disease in Turkey:a multicenter epidemiologic survey. J Clin Gastroenterol, 43:51-57, 2009
 
15) Victoria CR, et al:Incidence and prevalence rates of inflammatory bowel diseases, in midwestern of Sao Paulo State, Brazil. Arq Gastroenterol, 46:20-25, 2009
 

第2章 IBDの病因・病態

P.22 掲載の参考文献
1) Jostins L, et al:Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature, 491:119-124, 2012
PubMed
2) Ananthakrishnan AN:Environmental risk factors for inflammatory bowel diseases:a review. Dig Dis Sci, 60:290-298, 2015
PubMed
3) Knights D, et al:Advances in inflammatory bowel disease pathogenesis:linking host genetics and the microbiome. Gut, 62:1505-1510, 2013
PubMed
4) Ng SC, et al:Genetics of inflammatory bowel disease in Asia:systematic review and meta-analysis. Inflamm Bowel Dis, 18:1164-1176, 2012
PubMed
5) Calkins BM:A meta-analysis of the role of smoking in inflammatory bowel disease. Dig Dis Sci, 34:1841-1854, 1989
PubMed
6) Cosnes J, et al:Smoking cessation and the course of Crohn's disease:an intervention study. Gastroenterology, 120:1093-1099, 2001
PubMed
7) Benjamin JL, et al:Smokers with active Crohn's disease have a clinically relevant dysbiosis of the gastrointestinal microbiota. Inflamm Bowel Dis, 18:1092-1100, 2012
PubMed
8) Ananthakrishnan AN:Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol, 12:205-217, 2015
PubMed
9) Ng SC, et al:Environmental risk factors in inflammatory bowel disease:a population-based case-control study in Asia-Pacific. Gut, 64:1063-1071, 2015
 
10) Furusawa Y, et al:Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature, 504:446-450, 2013
PubMed
11) Sheehan D, et al:The microbiota in inflammatory bowel disease. J Gastroenterol, 50:495-507, 2015
PubMed
12) Matsuoka K & Kanai T:The gut microbiota and inflammatory bowel disease. Semin Immunopathol, 37:47-55, 2015
PubMed
13) Borody TJ & Khoruts A:Fecal microbiota transplantation and emerging applications. Nat Rev Gastroenterol Hepatol, 9:88-96, 2011
PubMed
14) Damman CJ, et al:The microbiome and inflammatory bowel disease:is there a therapeutic role for fecal microbiota transplantation? Am J Gastroenterol, 107:1452-1459, 2012
 
15) Imdad A, et al:Fecal transplantation for treatment of inflammatory bowel disease. Cochrane Database Syst Rev, 11:CD0127
 
P.42 掲載の参考文献
1) Nakase H, et al:The influence of cytokines on the complex pathology of ulcerative colitis. Autoimmun Rev, 21:103017, 2022
PubMed
2) Gabbani T, et al:The genetic burden of inflammatory bowel diseases:implications for the clinic? Expert Rev Gastroenterol Hepatol, 10:1109-1117, 2016
PubMed
3) Katsanos KH & Papadakis KA:Inflammatory Bowel Disease:Updates on Molecular Targets for Biologics. Gut Liver, 11:455-463, 2017
PubMed
4) Buisine MP, et al:Abnormalities in mucin gene expression in Crohn's disease. Inflamm Bowel Dis, 5:24-32, 1999
PubMed
5) Rakoff-Nahoum S, et al:Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell, 118:229-241, 2004
PubMed
6) Hart AL, et al:Characteristics of intestinal dendritic cells in inflammatory bowel diseases. Gastroenterology, 129:50-65, 2005
PubMed
7) Maloy KJ & Powrie F:Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature, 474:298-306, 2011
PubMed
8) Lazarevic V, et al:T-bet:a bridge between innate and adaptive immunity. Nat Rev Immunol, 13:777-789, 2013
 
9) Baumann C, et al:T-bet- and STAT4-dependent IL-33 receptor expression directly promotes antiviral Th1 cell responses. Proc Natl Acad Sci USA, 112:4056-4061, 2015
 
10) Iwata S, et al:The Transcription Factor T-bet Limits Amplification of Type I IFN Transcriptome and Circuitry in T Helper 1 Cells. Immunity, 46:983-991.e4, 2017
 
11) Cepek KL, et al:Integrin alpha E beta 7 mediates adhesion of T lymphocytes to epithelial cells. J Immunol, 150:3459-3470, 1993
PubMed
12) Lamb CA, et al:αEβ7 Integrin Identifies Subsets of Pro-Inflammatory Colonic CD4+ T Lymphocytes in Ulcerative Colitis. J Crohns Colitis, 11:610-620, 2017
 
13) Zheng W & Flavell RA:The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell, 89:587-596, 1997
 
14) Pastorelli L, et al:The role of IL-33 in gut mucosal inflammation. Mediators Inflamm, 2013:608187, 2013
 
15) Latiano A, et al:Associations between genetic polymorphisms in IL-33, IL1R1 and risk for inflammatory bowel disease. PLoS One, 8:e62144, 2013
PubMed
16) Korn T, et al:IL-17 and Th17 Cells. Annu Rev Immunol, 27:485-517, 2009
PubMed
17) Stockinger B & Omenetti S:The dichotomous nature of T helper 17 cells. Nat Rev Immunol, 17:535-544, 2017
PubMed
18) Ghoreschi K, et al:Generation of pathogenic T(H)17 cells in the absence of TGF-β signalling. Nature, 467:967-971, 2010
 
19) Lee Y, et al:Induction and molecular signature of pathogenic TH17 cells. Nat Immunol, 13:991-999, 2012
PubMed
20) Mangan PR, et al:Transforming growth factor-beta induces development of the T(H)17 lineage. Nature, 441:231-234, 2006
 
21) Bettelli E, et al:Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature, 441:235-238, 2006
PubMed
22) McGeachy MJ, et al:TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat Immunol, 8:1390-1397, 2007
 
23) Omenetti S, et al:The Intestine Harbors Functionally Distinct Homeostatic Tissue-Resident and Inflammatory Th17 Cells. Immunity, 51:77-89.e6, 2019
 
24) O'Connor W Jr, et al:A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat Immunol, 10:603-609, 2009
 
25) Hegazy AN, et al:Circulating and Tissue-Resident CD4(+) T Cells With Reactivity to Intestinal Microbiota Are Abundant in Healthy Individuals and Function Is Altered During Inflammation. Gastroenterology, 153:1320-1337.e16, 2017
 
26) Fina D, et al:Regulation of gut inflammation and th17 cell response by interleukin-21. Gastroenterology, 134:1038-1048, 2008
PubMed
27) Fujino S, et al:Increased expression of interleukin 17 in inflammatory bowel disease. Gut, 52:65-70, 2003
PubMed
28) Hueber W, et al:Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease:unexpected results of a randomised, double-blind placebo-controlled trial. Gut, 61:1693-1700, 2012
PubMed
29) Targan SR, et al:A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn's Disease. Am J Gastroenterol, 111:1599-1607, 2016
PubMed
30) Crotty S:T follicular helper cell differentiation, function, and roles in disease. Immunity, 41:529-542, 2014
PubMed
31) Zeng B, et al:ILC3 function as a double-edged sword in inflammatory bowel diseases. Cell Death Dis, 10:315, 2019
PubMed
32) Forkel M, et al:Distinct Alterations in the Composition of Mucosal Innate Lymphoid Cells in Newly Diagnosed and Established Crohn's Disease and Ulcerative Colitis. J Crohns Colitis, 13:67-78, 2019
PubMed
33) Josefowicz SZ, et al:Regulatory T cells:mechanisms of differentiation and function. Annu Rev Immunol, 30:531-564, 2012
PubMed
34) Veenbergen S & Samsom JN:Maintenance of small intestinal and colonic tolerance by IL-10-producing regulatory T cell subsets. Curr Opin Immunol, 24:269-276, 2012
PubMed
35) Worbs T, et al:Oral tolerance originates in the intestinal immune system and relies on antigen carriage by dendritic cells. J Exp Med, 203:519-527, 2006
PubMed
36) Davidson TS, et al:Cutting Edge:IL-2 is essential for TGF-beta-mediated induction of Foxp3+ T regulatory cells. J Immunol, 178:4022-4026, 2007
 
37) Kretschmer K, et al:Inducing and expanding regulatory T cell populations by foreign antigen. Nat Immunol, 6:1219-1227, 2005
PubMed
38) Chen W, et al:Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med, 198:1875-1886, 2003
PubMed
39) Mucida D, et al:Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science, 317:256-260, 2007
PubMed
40) Jaeger N, et al:Single-cell analyses of Crohn's disease tissues reveal intestinal intraepithelial T cells heterogeneity and altered subset distributions. Nat Commun, 12:1921, 2021
PubMed
41) Devlin JC, et al:Single-Cell Transcriptional Survey of Ileal-Anal Pouch Immune Cells From Ulcerative Colitis Patients. Gastroenterology, 160:1679-1693, 2021
PubMed
42) Wing JB & Sakaguchi S:Multiple treg suppressive modules and their adaptability. Front Immunol, 3:178, 2012
PubMed
43) Schiering C, et al:The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature, 513:564-568, 2014
PubMed
44) Ohnmacht C, et al:MUCOSAL IMMUNOLOGY. The microbiota regulates type 2 immunity through RORγt+ T cells. Science, 349:989-993, 2015
 
45) Kim KS, et al:Dietary antigens limit mucosal immunity by inducing regulatory T cells in the small intestine. Science, 351:858-863, 2016
PubMed
46) Jacobse J, et al:Intestinal Regulatory T Cells as Specialized Tissue-Restricted Immune Cells in Intestinal Immune Homeostasis and Disease. Front Immunol, 12:716499, 2021
PubMed
47) Vidarsson G, et al:IgG subclasses and allotypes:from structure to effector functions. Front Immunol, 5:520, 2014
PubMed
48) Baklien K & Brandtzaeg P:Comparative mapping of the local distribution of immunoglobulin-containing cells in ulcerative colitis and Crohn's disease of the colon. Clin Exp Immunol, 22:197-209, 1975
PubMed
49) Brandtzaeg P, et al:Immunohistochemical characterization of local immunoglobulin formation in ulcerative colitis. Gastroenterology, 66:1123-1136, 1974
PubMed
50) Macpherson A, et al:Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. Gut, 38:365-375, 1996
PubMed
51) Kett K, et al:Mucosal subclass distribution of immunoglobulin G-producing cells is different in ulcerative colitis and Crohn's disease of the colon. Gastroenterology, 93:919-924, 1987
PubMed
52) Martin JC, et al:Single-Cell Analysis of Crohn's Disease Lesions Identifies a Pathogenic Cellular Module Associated with Resistance to Anti-TNF Therapy. Cell, 178:1493-1508.e20, 2019
 
53) Uo M, et al:Mucosal CXCR4+ IgG plasma cells contribute to the pathogenesis of human ulcerative colitis through FcγR-mediated CD14 macrophage activation. Gut, 62:1734-1744, 2013
 
54) Castro-Dopico T & Clatworthy MR:Mucosal IgG in inflammatory bowel disease-a question of (sub)class? Gut Microbes, 12:1-9, 2020
PubMed
55) Quinton JF, et al:Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease:prevalence and diagnostic role. Gut, 42:788-791, 1998
PubMed
56) Choung RS, et al:Serologic microbial associated markers can predict Crohn's disease behaviour years before disease diagnosis. Aliment Pharmacol Ther, 43:1300-1310, 2016
PubMed
57) Han X, et al:Granulocyte-macrophage colony-stimulating factor autoantibodies in murine ileitis and progressive ileal Crohn's disease. Gastroenterology, 136:1261-71, e1, 2009
 
58) Onuma EK, et al:Autoimmunity in ulcerative colitis (UC):a predominant colonic mucosal B cell response against human tropomyosin isoform 5. Clin Exp Immunol, 121:466-471, 2000
 
59) Hibi T, et al:Enzyme linked immunosorbent assay (ELISA) and immunoprecipitation studies on anti-goblet cell antibody using a mucin producing cell line in patients with inflammatory bowel disease. Gut, 35:224-230, 1994
PubMed
60) Kuwada T, et al:Identification of an Anti-Integrin αvβ6 Autoantibody in Patients With Ulcerative Colitis. Gastroenterology, 160:2383-2394.e21, 2021
 
61) Kaser A, et al:Inflammatory bowel disease. Annu Rev Immunol, 28:573-621, 2010
PubMed
62) Castro-Dopico T, et al:Anti-commensal IgG Drives Intestinal Inflammation and Type 17 Immunity in Ulcerative Colitis. Immunity, 50:1099-1114.e10, 2019
 
63) Zhou MJ & Brown EJ:CR3 (Mac-1, alpha M beta 2, CD11b/CD18) and Fc gamma RIII cooperate in generation of a neutrophil respiratory burst:requirement for Fc gamma RIII and tyrosine phosphorylation. J Cell Biol, 125:1407-1416, 1994
 
64) van Montfoort N, et al:Fcγ receptor IIb strongly regulates Fcγ receptor-facilitated T cell activation by dendritic cells. J Immunol, 189:92-101, 2012
 

第3章 IBDの診断

P.51 掲載の参考文献
1) 潰瘍性大腸炎・クローン病診断基準・治療指針. 厚生労働科学研究費補助金 難治性疾患政策研究事業「難治性炎症性腸管障害に関する調査研究」(久松班)令和4年度分担研究報告書, 2023
 
P.61 掲載の参考文献
1) 潰瘍性大腸炎・クローン病診断基準・治療指針. 厚生労働科学研究費補助金 難治性疾患政策研究事業「難治性炎症性腸管障害に関する調査研究」(久松班)令和4年度分担研究報告書, 2023
 
2) 第二版 炎症性腸疾患の疾患活動性評価指標集. 厚生労働省研究費補助金 難治性疾患等政策研究事業「難治性炎症性腸管障害に関する調査研究」(鈴木班), 2020
 
3) 仲瀬裕志:家族性地中海熱遺伝子関連腸炎の内視鏡診断. 消化器内視鏡, 32:286-289, 2020
Medical*Online
4) Baumgart DC & Sandborn WJ:Crohn's disease. Lancet, 380:1590-1605, 2012
PubMed
5) Best WR, et al:Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology, 70:439-444, 1976
PubMed
6) IBD-QR from Tohoku University Hospital ホームページ https://www.gastroente.med.tohoku.ac.jp/ibdqr/ibd/(2023年7月閲覧)
 
7) Harvey RF & Bradshaw JM:A simple index of Crohn's-disease activity. Lancet, 1:514, 1980
 
8) 仲瀬裕志:MEFV遺伝子関連腸炎. 日本消化器病学会雑誌, 119:210-216, 2022
Medical*Online
9) 梅野淳嗣, 他:非特異性多発性小腸潰瘍症(CEAS)の病態と特徴. 日本消化器内視鏡学会雑誌, 62:1457-1466, 2020
 
10) 松岡克善, 他:日本人患者における便中カルプロテクチン検査の臨床的有用性. 医学と薬学, 74:717-726, 2017
Medical*Online
11) 高山茂雄, 他:ロイシンリッチα2グリコプロテイン測定試薬「ナノピアLRG」の開発と性能検討. 医学と薬学, 76:1769-1780, 2019
Medical*Online
12) Slaats J, et al:IL-1β/IL-6/CRP and IL-18/ferritin:Distinct Inflammatory Programs in Infections. PLoS Pathog, 12:e1005973, 2016
 

第4章 IBDにおける画像検査

P.67 掲載の参考文献
1) Khanna R, et al:Early combined immunosuppression for the management of Crohn's disease (REACT):a cluster randomised controlled trial. Lancet, 386:1825-1834, 2015
PubMed
2) Peyrin-Biroulet L, et al:Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE):Determining Therapeutic Goals for Treat-to-Target. Am J Gastroenterol, 110:1324-1338, 2015
PubMed
3) Turner D, et al:STRIDE-II:An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD):Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology, 160:1570-1583, 2021
 
4) Alfarone L, et al:Cross-Sectional Imaging Instead of Colonoscopy in Inflammatory Bowel Diseases:Lights and Shadows. J Clin Med, 11:, 2022
PubMed
5) Bartlett DJ, et al:Imaging Evaluation of Inflammatory Bowel Disease Complications. Gastrointest Endosc Clin N Am, 32:651-673, 2022
PubMed
6) Nakase H, et al:Treatment escalation and de-escalation decisions in Crohn's disease:Delphi consensus recommendations from Japan, 2021. J Gastroenterol, 58:313-345, 2023
PubMed
P.79 掲載の参考文献
1) Belvis Jimenez M, et al:Comparison of the Mayo Endoscopy Score and the Ulcerative Colitis Endoscopy Index of Severity and the Ulcerative Colitis Colonoscopy Index of Severity. Endosc Int Open, 9:E130-E136, 2021
PubMed
2) Travis SP, et al:Developing an instrument to assess the endoscopic severity of ulcerative colitis:the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut, 61:535-542, 2012
PubMed
3) Viscido A, et al:Systematic review and meta-analysis:the advantage of endoscopic Mayo score 0 over 1 in patients with ulcerative colitis. BMC Gastroenterol, 22:92, 2022
 
4) Irani NR, et al:Correlation Between Endoscopic and Histological Activity in Ulcerative Colitis Using Validated Indices. J Crohns Colitis, 12:1151-1157, 2018
PubMed
5) Daperno M, et al:Development and validation of a new, simplified endoscopic activity score for Crohn's disease:the SES-CD. Gastrointest Endosc, 60:505-512, 2004
PubMed
6) Rutgeerts P, et al:Predictability of the postoperative course of Crohn's disease. Gastroenterology, 99:956-963, 1990
PubMed
7) Mary JY & Modigliani R:Development and validation of an endoscopic index of the severity for Crohn's disease:a prospective multicentre study. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut, 30:983-989, 1989
 
8) Nakase H, et al:Treatment escalation and de-escalation decisions in Crohn's disease:Delphi consensus recommendations from Japan, 2021. J Gastroenterol, 58:313-345, 2023
PubMed
9) 潰瘍性大腸炎・クローン病診断基準・治療指針. 厚生労働科学研究費補助金 難治性疾患政策研究事業「難治性炎症性腸管障害に関する調査研究」(久松班)令和3年度分担研究報告書, 2022
 
10) Rondonotti E, et al:Small-bowel capsule endoscopy and device-assisted enteroscopy for diagnosis and treatment of small-bowel disorders:European Society of Gastrointestinal Endoscopy (ESGE) Technical Review. Endoscopy, 50:423-446, 2018
PubMed
11) Gralnek IM, et al:Development of a capsule endoscopy scoring index for small bowel mucosal inflammatory change. Aliment Pharmacol Ther, 27:146-154, 2008
PubMed
12) Gal E, et al:Assessment and validation of the new capsule endoscopy Crohn's disease activity index (CECDAI). Dig Dis Sci, 53:1933-1937, 2008
PubMed
13) Melmed GY, et al:Utility of video capsule endoscopy for longitudinal monitoring of Crohn's disease activity in the small bowel:a prospective study. Gastrointest Endosc, 88:947-955.e2, 2018
 
14) 「クローン病 MR enterography(MRE)アトラス」厚生労働科学研究費補助金 難治性疾患政策研究事業「難治性炎症性腸管障害に関する調査研究」(鈴木班), 2017年2月 http://www.ibdjapan.org/pdf/doc05.pdf(2023年7月閲覧)
 
15) Fiorino G, et al:MRI in Crohn's disease-current and future clinical applications. Nat Rev Gastroenterol Hepatol, 9:23-31, 2011
PubMed
16) Rimola J, et al:Magnetic resonance for assessment of disease activity and severity in ileocolonic Crohn's disease. Gut, 58:1113-1120, 2009
PubMed
17) Ordas I, et al:Accuracy of magnetic resonance enterography in assessing response to therapy and mucosal healing in patients with Crohn's disease. Gastroenterology, 146:374-82.e1, 2014
 

第5章 IBDの治療

P.83 掲載の参考文献
1) Inada R:Reports on severe colitis. Journal of Japanese Society of Gastroenterology. 27:625-38, 1928
 
2) 塩田広重:非特殊性限局性腸炎. 日医大誌, 10:1-12, 1939
 
3) Smolen JS, et al:Treating rheumatoid arthritis to target:recommendations of an international task force. Ann Rheum Dis, 69:631-637, 2010
PubMed
4) Leung CM, et al:Endoscopic and Histological Mucosal Healing in Ulcerative Colitis in the First Year of Diagnosis:Results from a Population-based Inception Cohort from Six Countries in Asia. J Crohns Colitis, 11:1440-1448, 2017
 
5) Shah SC, et al:Mucosal Healing Is Associated With Improved Long-term Outcomes of Patients With Ulcerative Colitis:A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol, 14:1245-1255.e8, 2016
 
6) De Cruz P, et al:Efficacy of thiopurines and adalimumab in preventing Crohn's disease recurrence in high-risk patients-a POCER study analysis. Aliment Pharmacol Ther, 42:867-879, 2015
PubMed
7) Turner D, et al:STRIDE-II:An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD):Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology, 160:1570-1583, 2021
 
8) Bessissow T, et al:Impact of Endoscopic and Histologic Activity on Disease Relapse in Ulcerative Colitis. Am J Gastroenterol, 117:1632-1638, 2022
PubMed
P.87 掲載の参考文献
1) 潰瘍性大腸炎・クローン病診断基準・治療指針. 厚生労働科学研究費補助金難治性疾患政策研究事業「難治性炎症性腸管障害に関する調査研究」(久松班)令和4年度分担研究報告書, 2023
 
P.88 掲載の参考文献
1) 潰瘍性大腸炎・クローン病診断基準・治療指針. 厚生労働科学研究費補助金難治性疾患政策研究事業「難治性炎症性腸管障害に関する調査研究」(久松班)令和4年度分担研究報告書, 2023
 
P.98 掲載の参考文献
1) Bohm SK & Kruis W:Long-term efficacy and safety of once-daily mesalazine granules for the treatment of active ulcerative colitis. Clin Exp Gastroenterol, 7:369-383, 2014
PubMed
2) Oh-Oka K, et al:Induction of Colonic Regulatory T Cells by Mesalamine by Activating the Aryl Hydrocarbon Receptor. Cell Mol Gastroenterol Hepatol, 4:135-151, 2017
PubMed
3) Naganuma M, et al:Measurement of colonic mucosal concentrations of 5-aminosalicylic acid is useful for estimating its therapeutic efficacy in distal ulcerative colitis:comparison of orally administered mesalamine and sulfasalazine. Inflammatory bowel diseases, 7:221-225, 2001
PubMed
4) Hiraoka S, et al:Multicenter survey on mesalamine intolerance in patients with ulcerative colitis. J Gastroenterol Hepatol, 36:137-143, 2021
PubMed
5) Azad Khan AK, et al:An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet, 2:892-895, 1977
PubMed
6) van Hees PA, et al:Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis:a study to determine the active therapeutic moiety of sulphasalazine. Gut, 21:632-635, 1980
 
7) Klotz U, et al:Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease. N Engl J Med, 303:1499-1502, 1980
PubMed
8) Nielsen OH:Sulfasalazine intolerance. A retrospective survey of the reasons for discontinuing treatment with sulfasalazine in patients with chronic inflammatory bowel disease. Scand J Gastroenterol, 17:389-393, 1982
PubMed
P.102 掲載の参考文献
1) Ramamoorthy S & Cidlowski JA:Corticosteroids:Mechanisms of Action in Health and Disease. Rheum Dis Clin North Am, 42:15-31, vii, 2016
PubMed
2) 杏林製薬株式会社:ペンタサ(R)注腸1gご使用にあたって. 2015 https://www.kyorin-pharm.co.jp/prodinfo/manual/ps0267.pdf(2023年7月閲覧)
 
3) Gomollon F, et al:3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016:Part 1:Diagnosis and Medical Management. J Crohns Colitis, 11:3-25, 2017
PubMed
4) 「炎症性腸疾患(IBD)診療ガイドライン 2020(改訂第2版)」(日本消化器病学会/編), 消化器病学会(南江堂/制作), 2020
 
P.105 掲載の参考文献
1) Tiede I, et al:CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest, 111:1133-1145, 2003
PubMed
2) Derijks LJ, et al:Review article:thiopurines in inflammatory bowel disease. Aliment Pharmacol Ther, 24:715-729, 2006
PubMed
3) Atreya R, et al:Novel signal transduction pathways:analysis of STAT-3 and Rac-1 signaling in inflammatory bowel disease. Ann N Y Acad Sci, 1072:98-113, 2006
PubMed
4) Kakuta Y, et al:NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease:a multicenter study. J Gastroenterol, 53:1065-1078, 2018
PubMed
5) 角田洋一 他:炎症性腸疾患における治療前スクリーニング-NUDT15 遺伝子多型測定の意義と課題-. 日本消化器病学会雑誌, 117:195-207, 2020
Medical*Online
P.109 掲載の参考文献
1) Liu J, et al:Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell, 66:807-815, 1991
PubMed
2) Stepkowski SM:Molecular targets for existing and novel immunosuppressive drugs. Expert Rev Mol Med, 2:1-23, 2000
PubMed
3) 「IBDを日常診療で診る」(日比紀文, 久松理一/編), 羊土社, 2017
 
4) Ogata H, et al:A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut, 55:1255-1262, 2006
PubMed
5) Nakase H:Acute Severe Ulcerative Colitis:Optimal Strategies for Drug Therapy. Gut Liver, 17:49-57, 2023
PubMed
6) Komaki Y, et al:Pharmacologic therapies for severe steroid refractory hospitalized ulcerative colitis:A network meta-analysis. J Gastroenterol Hepatol, 32:1143-1151, 2017
PubMed
7) Patocka J, et al:Cyclosporine A:Chemistry and Toxicity-A Review. Curr Med Chem, 28:3925-3934, 2021
PubMed
8) Nakase H, et al:Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol, 56:489-526, 2021
PubMed
9) Onodera M, et al:ATP-binding cassette subfamily B member 1 1236C/T polymorphism significantly affects the therapeutic outcome of tacrolimus in patients with refractory ulcerative colitis. J Gastroenterol Hepatol, 32:1562-1569, 2017
PubMed
10) Yamamoto Y, et al:CYP3A5 Genotype as a Potential Pharmacodynamic Biomarker for Tacrolimus Therapy in Ulcerative Colitis in Japanese Patients. Int J Mol Sci, 21:4347, 2020
PubMed
P.112 掲載の参考文献
1) Bamias G, et al:Targeting neutrophils in inflammatory bowel disease:revisiting the role of adsorptive granulocyte and monocyte apheresis. Expert Rev Gastroenterol Hepatol, 16:721-735, 2022
PubMed
2) Endo Y, et al:Novel adsorptive type apheresis device Immunopure for ulcerative colitis from clinical perspectives based on clinical trials:Japan and Europe. Ther Apher Dial, 25:432-436, 2021
PubMed
3) Sakuraba A, et al:An open-label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment. Am J Gastroenterol, 104:2990-2995, 2009
PubMed
4) Yoshimura N, et al:An open-label prospective randomized multicenter study of intensive versus weekly granulocyte and monocyte apheresis in active crohn's disease. BMC Gastroenterol, 15:163, 2015
PubMed
5) Zhu M, et al:The efficacy and safety of selective leukocytapheresis in the treatment of ulcerative colitis:a meta-analysis. Int J Colorectal Dis, 26:999-1007, 2011
PubMed
6) Yoshino T, et al:Efficacy and safety of granulocyte and monocyte adsorption apheresis for ulcerative colitis:a meta-analysis. Dig Liver Dis, 46:219-226, 2014
PubMed
7) Sigurbjornsson FT & Bjarnason I:Leukocytapheresis for the treatment of IBD. Nat Clin Pract Gastroenterol Hepatol, 5:509-516, 2008
PubMed
8) Kakimoto K, et al:Exploratory Study of the Effectiveness of Granulocyte and Monocyte Adsorptive Apheresis Before Initiation of Steroids in Patients With Active Ulcerative Colitis (EXPECT Study):A Multicenter Prospective Clinical Trial. Crohns Colitis 360,2:otaa073, 2020
PubMed
9) 「炎症性腸疾患(IBD)診療ガイドライン 2020(改訂第2版)」(日本消化器病学会/編), 消化器病学会(南江堂/制作), 2020
 
P.116 掲載の参考文献
1) 「炎症性腸疾患(IBD)診療ガイドライン 2020(改訂第2版)」(日本消化器病学会/編), 消化器病学会(南江堂/制作), 2020
 
2) Rutgeerts P, et al:Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med, 353:2462-2476, 2005
PubMed
3) Colombel JF, et al:Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med, 362:1383-1395, 2010
 
4) Matsumoto T, et al:Adalimumab Monotherapy and a Combination with Azathioprine for Crohn's Disease:A Prospective, Randomized Trial. J Crohns Colitis, 10:1259-1266, 2016
 
5) Hibi T, et al:Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis:a phase 3, double-blind, randomized, placebo-controlled study-(PURSUIT-J study). J Gastroenterol, 52:1101-1111, 2017
PubMed
6) Panes J, et al:Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis:SERENE UC Trial Results. Gastroenterology, 162:1891-1910, 2022
PubMed
7) Colombel JF, et al:Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med, 362:1383-1395, 2010
 
8) Panaccione R, et al:Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology, 146:392-400.e3, 2014
 
9) Kobayashi T, et al:Lack of Increased Risk of Lymphoma by Thiopurines or Biologics in Japanese Patients with Inflammatory Bowel Disease:A Large-Scale Administrative Database Analysis. J Crohns Colitis, 14:617-623, 2020
 
10) Kirchgesner J, et al:Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases. Gastroenterology, 155:337-346.e10, 2018
 
11) Bonovas S, et al:Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease:A Systematic Review and Network Meta-analysis. Clin Gastroenterol Hepatol, 14:1385-1397.e10, 2016
 
12) Lichtenstein GR, et al:Serious infection and mortality in patients with Crohn's disease:more than 5 years of follow-up in the TREAT(TM) registry. Am J Gastroenterol, 107:1409-1422, 2012
 
13) Lemaitre M, et al:Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease. JAMA, 318:1679-1686, 2017
 
14) Lichtenstein L, et al:Infliximab-Related Infusion Reactions:Systematic Review. J Crohns Colitis, 9:806-815, 2015
PubMed
P.119 掲載の参考文献
1) Xu M, et al:Regulation of antitumor immune responses by the IL-12 family cytokines, IL12, IL-23, and IL-27. Clin Dev Immunol, 2010:832454, 2010(published online)
 
2) Feagan BG, et al:Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. N Engl J Med, 375:1946-1960, 2016
PubMed
3) Sands BE, et al:Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med, 381:1201-1214, 2019
PubMed
P.121 掲載の参考文献
1) Thomas S & Baumgart DC:Targeting leukocyte migration and adhesion in Crohn's disease and ulcerative colitis. Inflammopharmacology, 20:1-18, 2012
PubMed
2) Neurath MF:Targeting immune cell circuits and trafficking in inflammatory bowel disease. Nat Immunol, 20:970-979, 2019
PubMed
3) Kobayashi T, et al:Ulcerative colitis. Nat Rev Dis Primers, 6:74, 2020
PubMed
4) Bellaguarda E, et al:Prevalence of Antibodies Against JC Virus in Patients With Refractory Crohn's Disease and Effects of Natalizumab Therapy. Clin Gastroenterol Hepatol, 13:1919-1925, 2015
PubMed
5) 潰瘍性大腸炎・クローン病診断基準・治療指針. 厚生労働科学研究費補助金 難治性疾患政策研究事業「難治性炎症性腸管障害に関する調査研究」(久松班)令和4年度分担研究報告書, 2023
 
P.124 掲載の参考文献
1) Villarino AV, et al:Mechanisms and consequences of Jak-STAT signaling in the immune system. Nat Immunol, 18:374-384, 2017
PubMed
2) Salas A, et al:JAK-STAT pathway targeting for the treatment of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol, 17:323-337, 2020
PubMed
3) Danese S, et al:JAK inhibition using tofacitinib for inflammatory bowel disease treatment:a hub for multiple inflammatory cytokines. Am J Physiol Gastrointest Liver Physiol, 310:G155-G162, 2016
PubMed
4) Choy EH:Clinical significance of Janus Kinase inhibitor selectivity. Rheumatology (Oxford), 58:953-962, 2019
PubMed
5) Traves PG, et al:JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib. Ann Rheum Dis, 80:865-875, 2021
PubMed
6) Sandborn WJ, et al:Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med, 376:1723-1736, 2017
PubMed
7) Feagan BG, et al:Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION):a phase 2b/3 double-blind, randomised, placebo-controlled trial. Lancet, 397:2372-2384, 2021
PubMed
8) Sandborn WJ, et al:Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis. Gastroenterology, 158:2139-2149.e14, 2020
 
9) Mease P, et al:Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data. Ann Rheum Dis, 79:1400-1413, 2020
PubMed
P.128 掲載の参考文献
1) Moschen AR, et al:IL-12, IL-23 and IL-17 in IBD:immunobiology and therapeutic targeting. Nat Rev Gastroenterol Hepatol, 16:185-196, 2019
PubMed
P.131 掲載の参考文献
1) Massironi S, et al:Understanding short bowel syndrome:Current status and future perspectives. Dig Liver Dis, 52:253-261, 2020
PubMed
2) Cheeseman CI & Tsang R:The effect of GIP and glucagon-like peptides on intestinal basolateral membrane hexose transport. Am J Physiol, 271:G477-G482, 1996
PubMed
3) Cheeseman CI:Upregulation of SGLT-1 transport activity in rat jejunum induced by GLP2 infusion in vivo. Am J Physiol, 273:R1965-R1971, 1997
PubMed
4) Cottrell JJ, et al:Glucagon-like peptide-2 protects against TPN-induced intestinal hexose malabsorption in enterally refed piglets. Am J Physiol Gastrointest Liver Physiol, 290:G293-G300, 2006
PubMed
5) Jeppesen PB, et al:Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology, 120:806-815, 2001
PubMed
6) Buchman AL, et al:Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's disease. Inflamm Bowel Dis, 16:962-973, 2010
PubMed
7) Kochar B, et al:Safety and Efficacy of Teduglutide (Gattex) in Patients With Crohn's Disease and Need for Parenteral Support Due to Short Bowel Syndrome-associated Intestinal Failure. J Clin Gastroenterol, 51:508-511, 2017
PubMed
P.134 掲載の参考文献
1) Lee MJ, et al:Efficacy of Medical Therapies for Fistulizing Crohn's Disease:Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol, 16:1879-1892, 2018
PubMed
2) Nakase H, et al:Treatment escalation and de-escalation decisions in Crohn's disease:Delphi consensus recommendations from Japan, 2021. J Gastroenterol, 2023
PubMed
3) Margiana R, et al:Clinical application of mesenchymal stem cell in regenerative medicine:a narrative review. Stem Cell Res Ther, 13:366, 2022
PubMed
4) Panes J, et al:Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease:a phase 3 randomised, double-blind controlled trial. Lancet, 388:1281-1290, 2016
PubMed
5) Panes J, et al:Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn's Disease. Gastroenterology, 154:1334-1342.e4, 2018
 
P.138 掲載の参考文献
1) 潰瘍性大腸炎・クローン病診断基準・治療指針. 厚生労働科学研究費補助金 難治性疾患政策研究事業「難治性炎症性腸管障害に関する調査研究」(久松班)令和4年度分担研究報告書, 2023
 
2) 鈴木康夫, 他:難治性炎症性腸管障害に関する調査研究 平成29年度総括・分担研究報告書. 厚生労働科学研究費補助金 難治性疾患等政策研究事業(難治性疾患政策研究事業), 2018
 
P.142 掲載の参考文献
1) 潰瘍性大腸炎・クローン病診断基準・治療指針. 厚生労働科学研究費補助金 難治性疾患政策研究事業「難治性炎症性腸管障害に関する調査研究」(久松班)令和4年度分担研究報告書, 2023
 
2) 鈴木康夫, 他:難治性炎症性腸管障害に関する調査研究 平成29年度総括・分担研究報告書. 厚生労働科学研究費補助金 難治性疾患等政策研究事業(難治性疾患政策研究事業), 2018
 

第6章 IBDの合併症

P.147 掲載の参考文献
1) Nakase H, et al:Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol, 56:489-526, 2021
PubMed
2) 厚生労働科学研究費補助金 難治性疾患等政策研究事業「炎症性腸疾患と合併症としての関節症状の実態調査(一次調査)」(猿田雅之, 他)平成30年度分担研究報告書, 2019
 
3) Karreman MC, et al:The Prevalence and Incidence of Axial and Peripheral Spondyloarthritis in Inflammatory Bowel Disease:A Systematic Review and Meta-analysis. J Crohns Colitis, 11:631-642, 2017
PubMed
4) Sieper J, et al:New criteria for inflammatory back pain in patients with chronic back pain:a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). Ann Rheum Dis, 68:784-788, 2009
PubMed
5) 潰瘍性大腸炎・クローン病診断基準・治療指針. 厚生労働科学研究費補助金 難治性疾患政策研究事業「難治性炎症性腸管障害に関する調査研究」(久松班)令和4年度分担研究報告書, 2023
 
6) Karreman MC, et al:The Prevalence and Incidence of Axial and Peripheral Spondyloarthritis in Inflammatory Bowel Disease:A Systematic Review and Meta-analysis. J Crohns Colitis, 11:631-642, 2017
PubMed
7) Rogler G, et al:Extraintestinal Manifestations of Inflammatory Bowel Disease:Current Concepts, Treatment, and Implications for Disease Management. Gastroenterology, 161:1118-1132, 2021
PubMed
P.150 掲載の参考文献
1) Gauss A, et al:Intestinal cytomegalovirus infection in patients hospitalized for exacerbation of inflammatory bowel disease:a 10-year tertiary referral center experience. Eur J Gastroenterol Hepatol, 27:712-720, 2015
PubMed
2) Okahara K, et al:Colonic cytomegalovirus detection by mucosal PCR and antiviral therapy in ulcerative colitis. PLoS One, 12:e0183951, 2017
PubMed
3) Romkens TE, et al:Cytomegalovirus in inflammatory bowel disease:A systematic review. World J Gastroenterol, 22:1321-1330, 2016
PubMed
4) Kandiel A & Lashner B:Cytomegalovirus colitis complicating inflammatory bowel disease. Am J Gastroenterol, 101:2857-2865, 2006
PubMed
5) Cottone M, et al:Prevalence of cytomegalovirus infection in severe refractory ulcerative and Crohn's colitis. Am J Gastroenterol, 96:773-775, 2001
PubMed
6) Pillet S, et al:Cytomegalovirus and ulcerative colitis:Place of antiviral therapy. World J Gastroenterol, 22:2030-2045, 2016
PubMed
7) Juric-Sekhar G, et al:Cytomegalovirus (CMV) in gastrointestinal mucosal biopsies:should a pathologist perform CMV immunohistochemistry if the clinician requests it? Hum Pathol, 60:11-15, 2017
PubMed
8) de Castro ML, et al:A comparative study of two histological techniques for the identification of cytomegalovirus infection in colorectal biopsies from patients with chronic inflammatory bowel disease. Rev Esp Enferm Dig, 101:697-705, 2009
PubMed
9) Chun J, et al:Usefulness of the cytomegalovirus antigenemia assay in patients with ulcerative colitis. Intest Res, 13:50-59, 2015
PubMed
10) Jang EY, et al:Diagnostic performance of the cytomegalovirus (CMV) antigenemia assay in patients with CMV gastrointestinal disease. Clin Infect Dis, 48:e121-e124, 2009
PubMed
11) Kim JW, et al:Clinical utility of cytomegalovirus antigenemia assay and blood cytomegalovirus DNA PCR for cytomegaloviral colitis patients with moderate to severe ulcerative colitis. J Crohns Colitis, 8:693-701, 2014
PubMed
12) Nagata N, et al:Diagnostic value of antigenemia assay for cytomegalovirus gastrointestinal disease in immunocompromised patients. World J Gastroenterol, 17:1185-1191, 2011
PubMed
13) Yoshino T, et al:Usefulness of quantitative real-time PCR assay for early detection of cytomegalovirus infection in patients with ulcerative colitis refractory to immunosuppressive therapies. Inflamm Bowel Dis, 13:1516-1521, 2007
PubMed
14) Kou T, et al:Cytomegalovirus infection in patients with ulcerative colitis diagnosed by quantitative real-time PCR analysis. Dig Dis Sci, 51:1052-1055, 2006
PubMed
15) Yokoyama Y, et al:Current Diagnostic and Therapeutic Approaches to Cytomegalovirus Infections in Ulcerative Colitis Patients Based on Clinical and Basic Research Data. Int J Mol Sci, 21:, 2020
PubMed
16) Yamawaka T, et al:The association between antigenemia, histology with immunohistochemistry, and mucosal PCR in the diagnosis of ulcerative colitis with concomitant human cytomegalovirus infection. J Gastroenterol, 58:44-52, 2023
PubMed
17) CDI 診療ガイドライン作成委員会:Clostridioides(Clostridium)difficile 感染症診療ガイドライン. 感染症誌, 92:819-854, 2018
 
P.153 掲載の参考文献
1) Yuhara H, et al:Meta-analysis:the risk of venous thromboembolism in patients with inflammatory bowel disease. Aliment Pharmacol Ther, 37:953-962, 2013
PubMed
2) 厚生労働科学研究費補助金 難治性疾患等政策研究事業「合併症/副作用への対策プロジェクト炎症性腸疾患における血栓症発症の予防・治療に関する研究」(藤谷幹浩, 他)平成30年度分担研究報告書, 2018
 
3) Ando K, et al:The incidence and risk factors of venous thromboembolism in Japanese inpatients with inflammatory bowel disease:a retrospective cohort study. Intest Res, 16:416-425, 2018
PubMed
4) Naito T, et al:Prevalence and Effect of Genetic Risk of Thromboembolic Disease in Inflammatory Bowel Disease. Gastroenterology, 160:771-780.e4, 2021
 
5) Olivera PA, et al:International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease. Nat Rev Gastroenterol Hepatol, 18:857-873, 2021
PubMed
P.157 掲載の参考文献
1) Choi CH, et al:Forty-Year Analysis of Colonoscopic Surveillance Program for Neoplasia in Ulcerative Colitis:An Updated Overview. Am J Gastroenterol, 110:1022-1034, 2015
PubMed
2) Kishikawa J, et al:Results of a 36-year surveillance program for ulcerative colitis-associated neoplasia in the Japanese population. Dig Endosc, 30:236-244, 2018
PubMed
3) Laine L, et al:SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. Gastroenterology, 148:639-651.e28, 2015
 
4) Watanabe T, et al:Comparison of Targeted vs Random Biopsies for Surveillance of Ulcerative Colitis-Associated Colorectal Cancer. Gastroenterology, 151:1122-1130, 2016
PubMed
5) Mizushima T, et al:Malignancy in Crohn's disease:incidence and clinical characteristics in Japan. Digestion, 81:265-270, 2010
PubMed
6) Fujita M, et al:Genomic landscape of colitis-associated cancer indicates the impact of chronic inflammation and its stratification by mutations in the Wnt signaling. Oncotarget, 9:969-981, 2018
PubMed
7) 杉田 昭 ほか:クローン病に合併する直腸肛門管癌. 日本消化器病学会, 110:396-402, 2013
Medical*Online
8) Sasaki H, et al:Clinicopathological characteristics of cancer associated with Crohn's disease. Surg Today, 47:35-41, 2017
PubMed
9) 桑原隆一ほか:クローン病に対する腸管切除症例1,143例の検討日本消化器外科学会雑誌. 51:671-679, 2018
 
10) 東 大二郎 ほか:Crohn 病における縫合不全の予防と対策. 日本大腸肛門病会誌, 62:818-822, 2009
 
11) Widmar M, et al:Small bowel adenocarcinoma in Crohn's disease. J Gastrointest Surg, 15:797-802, 2011
PubMed
12) Hussain T, et al:Small bowel adenocarcinoma in Crohn's disease:a rare but devastating complication. Tech Coloproctol, 24:1055-1062, 2020
PubMed
13) Riddell RH, et al:Dysplasia in inflammatory bowel disease:standardized classification with provisional clinical applications. Hum Pathol, 14:931-968, 1983
PubMed
14) 武藤徹一郎 ほか:潰瘍性大腸炎に出現する異型上皮の病理組織学的判定基準 surveillance colonoscopy への応用を目的とした新判定基準の提案. 日本大腸肛門病学会雑誌, 47:547-551, 1994
 
P.160 掲載の参考文献
1) Karnsund S, et al:Systematic review of the prevalence and development of osteoporosis or low bone mineral density and its risk factors in patients with inflammatory bowel disease. World J Gastroenterol, 26:5362-5374, 2020
PubMed
2) Lo B, et al:Incidence, Risk Factors and Evaluation of Osteoporosis in Patients With Inflammatory Bowel Disease:A Danish Population-Based Inception Cohort With 10 Years of Follow-Up. J Crohns Colitis, 14:904-914, 2020
PubMed
3) Chen LK, et al:Asian Working Group for Sarcopenia:2019 Consensus Update on Sarcopenia Diagnosis and Treatment. J Am Med Dir Assoc, 21:300-307.e2, 2020
 
4) Singh A, et al:Evaluation of Nutritional Characteristics Reveals Similar Prevalence of Malnutrition in Patients with Ulcerative Colitis and Crohn's Disease. Dig Dis Sci, 68:580-595, 2023
PubMed
5) Mager DR, et al:Vitamin D status and risk for sarcopenia in youth with inflammatory bowel diseases. Eur J Clin Nutr, 72:623-626, 2018
PubMed
6) Shimizu Y:Gut microbiota in common elderly diseases affecting activities of daily living. World J Gastroenterol, 24:4750-4758, 2018
PubMed
7) Buigues C, et al:Effect of a Prebiotic Formulation on Frailty Syndrome:A Randomized, Double-Blind Clinical Trial. Int J Mol Sci, 17, 2016
PubMed
P.164 掲載の参考文献
1) 田中 篤, 滝川 一:第2回 硬化性胆管炎の疫学 原発性硬化性胆管炎・IgG4関連硬化性胆管炎の疫学. 胆道, 30:304-311, 2016
Medical*Online
2) Broome U & Bergquist A:Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer. Semin Liver Dis, 26:31-41, 2006
PubMed
3) 田中 篤:原発性硬化性胆管炎(PSC)の up-to-date. 胆道, 32:241-250, 2018
Medical*Online
4) Henriksen EK, et al:Update on primary sclerosing cholangitis genetics. Curr Opin Gastroenterol, 30:310-319, 2014
PubMed
5) Ji SG, et al:Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease. Nat Genet, 49:269-273, 2017
PubMed
6) Ichikawa M, et al:Bacteriophage therapy against pathological Klebsiella pneumoniae ameliorates the course of primary sclerosing cholangitis. Nat Commun, 14:3261, 2023
PubMed
7) 潰瘍性大腸炎・クローン病診断基準・治療指針. 厚生労働科学研究費補助金 難治性疾患政策研究事業「難治性炎症性腸管障害に関する調査研究」(久松班)令和4年度分担研究報告書, 2023
 
P.169 掲載の参考文献
1) Diaconescu S, et al:Dermatological Manifestations in Pediatric Inflammatory Bowel Disease. Medicina (Kaunas), 56:425, 2020
PubMed
2) Weinstein M, et al:Erythema nodosum as a presentation of inflammatory bowel disease. CMAJ, 173:145-146, 2005
PubMed
3) 潰瘍性大腸炎・クローン病診断基準・治療指針. 厚生労働科学研究費補助金 難治性疾患政策研究事業「難治性炎症性腸管障害に関する調査研究」(久松班)令和4年度分担研究報告書, 2023
 
4) Jang HJ, et al:The difference in extraintestinal manifestations of inflammatory bowel disease for children and adults. Transl Pediatr, 8:4-15, 2019
PubMed
5) Marzano AV, et al:Cutaneous manifestations in patients with inflammatory bowel diseases:pathophysiology, clinical features, and therapy. Inflamm Bowel Dis, 20:213-227, 2014
PubMed
6) Becuwe C, et al:Sweet's syndrome associated with Crohn's disease. Acta Derm Venereol, 69:444-445, 1989
PubMed
7) Marzano AV, et al:A Comprehensive Review of Neutrophilic Diseases. Clin Rev Allergy Immunol, 54:114-130, 2018
PubMed
8) Tillack C, et al:Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut, 63:567-577, 2014
 

第7章 IBDのspecial situation

P.175 掲載の参考文献
1) Jeuring SF, et al:Epidemiology and Long-term Outcome of Inflammatory Bowel Disease Diagnosed at Elderly Age-An Increasing Distinct Entity? Inflamm Bowel Dis, 22:1425-1434, 2016
PubMed
2) Tran V, et al:IBD in the Elderly:Management Challenges and Therapeutic Considerations. Curr Gastroenterol Rep, 21:60, 2019
PubMed
3) Ananthakrishnan AN, et al:Systematic Review and Meta-analysis:Phenotype and Clinical Outcomes of Older-onset Inflammatory Bowel Disease. J Crohns Colitis, 10:1224-1236, 2016
PubMed
4) Charpentier C, et al:Natural history of elderly-onset inflammatory bowel disease:a population-based cohort study. Gut, 63:423-432, 2014
PubMed
5) Komoto S, et al:Clinical differences between elderly-onset ulcerative colitis and non-elderly-onset ulcerative colitis:A nationwide survey data in Japan. J Gastroenterol Hepatol, 33:1839-1843, 2018
PubMed
6) Ando K, et al:The incidence and risk factors of venous thromboembolism in Japanese inpatients with inflammatory bowel disease:a retrospective cohort study. Intest Res, 16:416-425, 2018
PubMed
7) Kochar B, et al:Pretreatment Frailty Is Independently Associated With Increased Risk of Infections After Immunosuppression in Patients With Inflammatory Bowel Diseases. Gastroenterology, 158:2104-2111.e2, 2020
 
8) Brassard P, et al:Oral corticosteroids and the risk of serious infections in patients with elderly-onset inflammatory bowel diseases. Am J Gastroenterol, 109:1795-802;quiz 1803, 2014
 
9) Peyrin-Biroulet L, et al:Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology, 141:1621-28.e1, 2011
 
10) Beaugerie L, et al:Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease:a prospective observational cohort study. Lancet, 374:1617-1625, 2009
PubMed
11) Fukata N, et al:Hematologic malignancies in the Japanese patients with inflammatory bowel disease. J Gastroenterol, 49:1299-1306, 2014
PubMed
12) Kobayashi T, et al:Lack of Increased Risk of Lymphoma by Thiopurines or Biologics in Japanese Patients with Inflammatory Bowel Disease:A Large-Scale Administrative Database Analysis. J Crohns Colitis, 14:617-623, 2020
 
13) Cheng D, et al:Safety and Efficacy of Tumor Necrosis Factor Antagonists in Older Patients With Ulcerative Colitis:Patient-Level Pooled Analysis of Data From Randomized Trials. Clin Gastroenterol Hepatol, 19:939-946.e4, 2021
 
14) Porcari S, et al:Persistence on Anti-Tumour Necrosis Factor Therapy in Older Patients with Inflammatory Bowel Disease Compared with Younger Patients:Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD). Drugs Aging, 37:383-392, 2020
 
15) Cottone M, et al:Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol, 9:30-35, 2011
PubMed
16) Calafat M, et al:Risk of Immunomediated Adverse Events and Loss of Response to Infliximab in Elderly Patients with Inflammatory Bowel Disease:A Cohort Study of the ENEIDA Registry. J Crohns Colitis, 16:946-953, 2022
PubMed
17) Chaparro M, et al:Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain:Large-Scale Epidemiological Study. J Clin Med, 10:2885, 2021
 
18) Desai A, et al:Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis, 19:309-315, 2013
 
19) Singh S, et al:Early combined immunosuppression may be effective and safe in older patients with Crohn's disease:post hoc analysis of REACT. Aliment Pharmacol Ther, 49:1188-1194, 2019
PubMed
20) Pugliese D, et al:Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease:the IG-IBD LIVE study. Aliment Pharmacol Ther, 56:95-109, 2022
 
21) Khan N, et al:Efficacy of Vedolizumab in a Nationwide Cohort of Elderly Inflammatory Bowel Disease Patients. Inflamm Bowel Dis, 28:734-744, 2022
 
22) Bollegala N, et al:Increased Postoperative Mortality and Complications Among Elderly Patients With Inflammatory Bowel Diseases:An Analysis of the National Surgical Quality Improvement Program Cohort. Clin Gastroenterol Hepatol, 14:1274-1281, 2016
PubMed
23) Ikeuchi H, et al:Prognosis following emergency surgery for ulcerative colitis in elderly patients. Surg Today, 44:39-43, 2014
PubMed
24) Bewtra M, et al:Mortality associated with medical therapy versus elective colectomy in ulcerative colitis:a cohort study. Ann Intern Med, 163:262-270, 2015
PubMed
P.186 掲載の参考文献
1) van Rheenen PF, et al:The Medical Management of Paediatric Crohn's Disease:an ECCO-ESPGHAN Guideline Update. J Crohns Colitis:171-194, 2020
 
2) Van Limbergen J, et al:Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology, 135:1114-1122, 2008
PubMed
3) Vernier-Massouille G, et al:Natural history of pediatric Crohn's disease:a population-based cohort study. Gastroenterology, 135:1106-1113, 2008
PubMed
4) Arai K, et al:Phenotypic characteristics of pediatric inflammatory bowel disease in Japan:results from a multicenter registry. Intest Res, 18:412-420, 2020
PubMed
5) Ajbar A, et al:Diagnostic Delay in Pediatric Inflammatory Bowel Disease:A Systematic Review. Dig Dis Sci, 67:5444-5454, 2022
PubMed
6) Heuschkel R, et al:Guidelines for the management of growth failure in childhood inflammatory bowel disease. Inflamm Bowel Dis, 14:839-849, 2008
PubMed
7) Olen O, et al:Childhood onset inflammatory bowel disease and risk of cancer:a Swedish nationwide cohort study 1964-2014. BMJ, 358:j3951, 2017
 
8) Olen O, et al:Increased Mortality of Patients With Childhood-Onset Inflammatory Bowel Diseases, Compared With the General Population. Gastroenterology, 156:614-622, 2019
PubMed
9) Kuenzig ME, et al:Inflammatory Bowel Disease Increases the Risk of Venous Thromboembolism in Children:A Population-Based Matched Cohort Study. J Crohns Colitis, 15:2031-2040, 2021
PubMed
10) Uhlig HH, et al:The diagnostic approach to monogenic very early onset inflammatory bowel disease. Gastroenterology, 147:990-1007.e3, 2014
 
11) 潰瘍性大腸炎・クローン病診断基準・治療指針. 厚生労働科学研究費補助金 難治性疾患政策研究事業「難治性炎症性腸管障害に関する調査研究」(久松班)令和4年度分担研究報告書, 2023
 
12) Turner D, et al:Appraisal of the pediatric ulcerative colitis activity index (PUCAI). Inflamm Bowel Dis, 15:1218-1223, 2009
PubMed
13) Turner D, et al:Appraisal of the pediatric Crohn's disease activity index on four prospectively collected datasets:recommended cutoff values and clinimetric properties. Am J Gastroenterol, 105:2085-2092, 2010
PubMed
14) Hyams JS, et al:Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr, 12:439-447, 1991
PubMed
15) Shimizu H, et al:Both fecal calprotectin and fecal immunochemical tests are useful in children with inflammatory bowel disease. J Gastroenterol, 57:344-356, 2022
PubMed
16) van Wassenaer EA, et al:The child's perception on monitoring inflammatory bowel disease activity. Eur J Pediatr, 181:1143-1149, 2022
PubMed
17) Hyams JS, et al:Clinical and biological predictors of response to standardised paediatric colitis therapy (PROTECT):a multicentre inception cohort study. Lancet, 393:1708-1720, 2019
PubMed
18) Turner D, et al:STRIDE-II:An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD):Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology, 160:1570-1583, 2021
 
19) Ishige T, et al:Expert consensus on vaccination in patients with inflammatory bowel disease in Japan. J Gastroenterol, 58:135-157, 2023
PubMed
20) Bachmann J, et al:Epstein-Barr Virus Prevalence at Diagnosis and Seroconversion during Follow-Up in Pediatric Inflammatory Bowel Disease. J Clin Med, 10:5187, 2021
PubMed
P.192 掲載の参考文献
1) Beaugerie L, et al:Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer. Gut, 63:1416-1423, 2014
 
2) Wu S, et al:Inflammatory Bowel Disease and Long-term Risk of Cancer:A Prospective Cohort Study Among Half a Million Adults in UK Biobank. Inflamm Bowel Dis, 29:384-395, 2023
 
3) 潰瘍性大腸炎・クローン病診断基準・治療指針. 厚生労働科学研究費補助金 難治性疾患政策研究事業「難治性炎症性腸管障害に関する調査研究」(久松班)令和4年度分担研究報告書, 2023
 
4) Annese V, et al:European Evidence-based Consensus:Inflammatory Bowel Disease and Malignancies. J Crohns Colitis, 9:945-965, 2015
PubMed
5) Penn I:The effect of immunosuppression on pre-existing cancers. Transplantation, 55:742-747, 1993
PubMed
6) Dixon WG, et al:Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy:results from the British Society for Rheumatology Biologics Register. Arthritis Care Res (Hoboken), 62:755-763, 2010
 
7) Waljee AK, et al:Anti-tumour necrosis factor-α therapy and recurrent or new primary cancers in patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis and previous cancer in Denmark:a nationwide, population-based cohort study. Lancet Gastroenterol Hepatol, 5:276-284, 2020
 
8) Shelton E, et al:Cancer Recurrence Following Immune-Suppressive Therapies in Patients With Immune-Mediated Diseases:A Systematic Review and Meta-analysis. Gastroenterology, 151:97-109.e4, 2016
 
9) Poullenot F, et al:Comparative Risk of Incident Cancer in Patients with Inflammatory Bowel Disease with Prior Non-digestive Malignancy According to Immunomodulator:a Multicentre Cohort Study. J Crohns Colitis, 16:1523-1530, 2022
PubMed
10) Lin SC, et al:The Treatment of Inflammatory Bowel Disease in Patients With a History of Malignancy. Inflamm Bowel Dis, 25:998-1005, 2019
PubMed
11) Sandborn WJ, et al:Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med, 376:1723-1736, 2017
PubMed
12) Lee EB, et al:Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med, 370:2377-2386, 2014
PubMed
13) Petrelli F, et al:Association of steroid use with survival in solid tumours. Eur J Cancer, 141:105-114, 2020
PubMed
14) Axelrad JE, et al:Effects of cancer treatment on inflammatory bowel disease remission and reactivation. Clin Gastroenterol Hepatol, 10:1021-7.e1, 2012
 
15) Amiot A, et al:Management of immune checkpoint inhibitor in patients with cancer and pre-existing inflammatory bowel disease:Recommendations from the GETAID. Dig Liver Dis, 54:1162-1167, 2022
 
16) van der Kooij MK, et al:Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease :A Cohort Study. Ann Intern Med, 174:641-648, 2021
PubMed
17) Meserve J, et al:Systematic review with meta-analysis:safety and tolerability of immune checkpoint inhibitors in patients with pre-existing inflammatory bowel diseases. Aliment Pharmacol Ther, 53:374-382, 2021
PubMed
P.199 掲載の参考文献
1) 潰瘍性大腸炎・クローン病診断基準・治療指針. 厚生労働科学研究費補助金 難治性疾患政策研究事業「難治性炎症性腸管障害に関する調査研究」(久松班)令和4年度分担研究報告書, 2023
 
2) Marri SR, et al:Voluntary childlessness is increased in women with inflammatory bowel disease. Inflamm Bowel Dis, 13:591-599, 2007
PubMed
3) Mountifield R, et al:Fear and fertility in inflammatory bowel disease:a mismatch of perception and reality affects family planning decisions. Inflamm Bowel Dis, 15:720-725, 2009
PubMed
4) Gallinger ZR, et al:Perceptions and Attitudes Towards Medication Adherence during Pregnancy in Inflammatory Bowel Disease. J Crohns Colitis, 10:892-897, 2016
PubMed
5) Kim MA, et al:The Influence of Disease Activity on Pregnancy Outcomes in Women With Inflammatory Bowel Disease:A Systematic Review and Meta-Analysis. J Crohns Colitis, 15:719-732, 2021
PubMed
6) Watanabe C, et al:Non-adherence to Medications in Pregnant Ulcerative Colitis Patients Contributes to Disease Flares and Adverse Pregnancy Outcomes. Dig Dis Sci, 66:577-586, 2021
PubMed
7) Kushner T, et al:Women's Willingness to Accept Risks of Medication for Inflammatory Bowel Disease During Pregnancy. Patient, 15:353-365, 2022
PubMed
8) 厚生労働科学研究費補助金 難治性疾患等政策研究事業(難治性疾患政策研究事業)「全身性エリテマトーデス(SLE), 関節リウマチ(RA), 若年性特発性関節炎(JIA)や炎症性腸疾患(IBD)罹患女性患者の妊娠, 出産を考えた治療指針」[「関節リウマチ(RA)や炎症性腸疾患(IBD)罹患女性患者の妊娠, 出産を考えた治療指針の作成」研究班]平成30年3月, 2018 https://ra-ibd-sle-pregnancy.org/data/sisin201803.pdf(2023年7月閲覧)
 
9) Heetun ZS, et al:Review article:Reproduction in the patient with inflammatory bowel disease. Aliment Pharmacol Ther, 26:513-533, 2007
PubMed
10) Waljee A, et al:Threefold increased risk of infertility:a meta-analysis of infertility after ileal pouch anal anastomosis in ulcerative colitis. Gut, 55:1575-1580, 2006
PubMed
11) Bartels SA, et al:Significantly increased pregnancy rates after laparoscopic restorative proctocolectomy:a cross-sectional study. Ann Surg, 256:1045-1048, 2012
PubMed
12) de Lima A, et al:A prospective study of the safety of lower gastrointestinal endoscopy during pregnancy in patients with inflammatory bowel disease. J Crohns Colitis, 9:519-524, 2015
 
13) Kammerlander H, et al:Fecal Calprotectin During Pregnancy in Women With Moderate-Severe Inflammatory Bowel Disease. Inflamm Bowel Dis, 24:839-848, 2018
PubMed
14) 具 潤亜 ほか:妊娠・出産を希望されるIBD 患者の診療を身につける. IBD reserch, 17:34-40, 2023
 
15) Bortoli A, et al:Pregnancy outcome in inflammatory bowel disease:prospective European case-control ECCO-EpiCom study, 2003-2006. Aliment Pharmacol Ther, 34:724-734, 2011
PubMed
16) Broms G, et al:Birth outcomes in women with inflammatory bowel disease:effects of disease activity and drug exposure. Inflamm Bowel Dis, 20:1091-1098, 2014
PubMed
17) Chaparro M, et al:Surgery due to Inflammatory Bowel Disease During Pregnancy:Mothers and Offspring Outcomes From an ECCO Confer Multicentre Case Series [Scar Study]. J Crohns Colitis, 16:1428-1435, 2022
PubMed
18) Naganuma M, et al:Conception and pregnancy outcome in women with inflammatory bowel disease:A multicentre study from Japan. J Crohns Colitis, 5:317-323, 2011
PubMed
19) Cleary BJ & Kallen B:Early pregnancy azathioprine use and pregnancy outcomes. Birth Defects Res A Clin Mol Teratol, 85:647-654, 2009
PubMed
20) Mahadevan U, et al:Pregnancy and Neonatal Outcomes After Fetal Exposure to Biologics and Thiopurines Among Women With Inflammatory Bowel Disease. Gastroenterology, 160:1131-1139, 2021
PubMed
21) Meyer A, et al:Comparative study of pregnancy outcomes in women with inflammatory bowel disease treated with thiopurines and/or anti-TNF:a French nationwide study 2010-2018. Aliment Pharmacol Ther, 54:302-311, 2021
PubMed
22) Kanis SL, et al:Anti-TNF Levels in Cord Blood at Birth are Associated with Anti-TNF Type. J Crohns Colitis, 12:939-947, 2018
PubMed
23) Nielsen OH, et al:Biologics for Inflammatory Bowel Disease and Their Safety in Pregnancy:A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol, 20:74-87.e3, 2022
 
24) Luu M, et al:Continuous Anti-TNFα Use Throughout Pregnancy:Possible Complications For the Mother But Not for the Fetus. A Retrospective Cohort on the French National Health Insurance Database (EVASION). Am J Gastroenterol, 113:1669-1677, 2018
 
25) Thomas C, et al:A Severe Neonatal Lymphopenia Associated With Administration of Azathioprine to the Mother in a Context of Crohn's Disease. J Crohns Colitis, 12:258-261, 2018
 
P.206 掲載の参考文献
1) Kennedy NA, et al:British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic. Gut, 69:984-990, 2020
PubMed
2) Nakase H, et al:Expert Opinions on the Current Therapeutic Management of Inflammatory Bowel Disease during the COVID-19 Pandemic:Japan IBD COVID-19 Taskforce, Intractable Diseases, the Health and Labor Sciences Research. Digestion, 102:814-822, 2021
PubMed
3) Lees CW, et al:Withdrawal of the British Society of Gastroenterology IBD risk grid for COVID-19 severity. Gut, 72:410-412, 2023
PubMed
4) Rizzello F, et al:COVID-19 in IBD:The experience of a single tertiary IBD center. Dig Liver Dis, 53:271-276, 2021
PubMed
5) Hadi Y, et al:Incidence, outcomes, and impact of COVID-19 on inflammatory bowel disease:propensity matched research network analysis. Aliment Pharmacol Ther, 55:191-200, 2022
 
6) Gubatan J, et al:SARS-CoV-2 Testing, Prevalence, and Predictors of COVID-19 in Patients with Inflammatory Bowel Disease in Northern California. Gastroenterology, 159:1141-1144.e2, 2020
 
7) Agrawal M, et al:COVID-19 Outcomes Among Racial and Ethnic Minority Individuals With Inflammatory Bowel Disease in the United States. Clin Gastroenterol Hepatol, 19:2210-2213.e3, 2021
 
8) Parekh R, et al:Presence of Comorbidities Associated with Severe Coronavirus Infection in Patients with Inflammatory Bowel Disease. Dig Dis Sci, 67:1271-1277, 2022
PubMed
9) Ricciuto A, et al:Inflammatory Bowel Disease Clinical Activity is Associated with COVID-19 Severity Especially in Younger Patients. J Crohns Colitis, 16:591-600, 2022
PubMed
10) Ungaro RC, et al:Impact of Medications on COVID-19 Outcomes in Inflammatory Bowel Disease:Analysis of More Than 6000 Patients From an International Registry. Gastroenterology, 162:316-319.e5, 2022
 
11) Nakase H, et al:Interim analysis of a multicenter registry study of COVID-19 patients with inflammatory bowel disease in Japan (J-COSMOS). J Gastroenterol, 57:174-184, 2022
PubMed
12) Meyer A, et al:Risk of severe COVID-19 in patients treated with IBD medications:a French nationwide study. Aliment Pharmacol Ther, 54:160-166, 2021
PubMed
13) Dorrington AM, et al:The Historical Role and Contemporary Use of Corticosteroids in Inflammatory Bowel Disease. J Crohns Colitis, 14:1316-1329, 2020
PubMed
14) Rubin DT, et al:Management of Patients With Crohn's Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic:Results of an International Meeting. Gastroenterology, 159:6-13.e6, 2020
 
15) Burke KE, et al:Immunosuppressive Therapy and Risk of COVID-19 Infection in Patients With Inflammatory Bowel Diseases. Inflamm Bowel Dis, 27:155-161, 2021
PubMed
16) Ungaro RC, et al:Effect of IBD medications on COVID-19 outcomes:results from an international registry. Gut, 70:725-732, 2021
 
17) Nakase H, et al:Final analysis of COVID-19 patients with inflammatory bowel disease in Japan (JCOSMOS):a multicenter registry cohort study. Gastro Hep Advances, 2023 (inpress)
 
18) Singh AK, et al:Risk and outcomes of coronavirus disease in patients with inflammatory bowel disease:A systematic review and meta-analysis. United European Gastroenterol J, 9:159-176, 2021
PubMed
19) Brenner EJ, et al:Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases:Results From an International Registry. Gastroenterology, 159:481-491.e3, 2020
 
20) Tripathi K, et al:COVID-19 and Outcomes in Patients With Inflammatory Bowel Disease:Systematic Review and Meta-Analysis. Inflamm Bowel Dis, 28:1265-1279, 2022
PubMed
21) Velayos FS, et al:Prior Immunosuppressive Therapy and Severe Illness Among Patients Diagnosed with SARS-CoV-2:a Community-Based Study. J Gen Intern Med, 36:3794-3801, 2021
PubMed
22) Guimaraes PO, et al:Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia. N Engl J Med, 385:406-415, 2021
PubMed
23) Singh S, et al:Risk of Severe Coronavirus Disease 2019 in Patients With Inflammatory Bowel Disease in the United States:A Multicenter Research Network Study. Gastroenterology, 159:1575-1578.e4, 2020
 
24) Lukin DJ, et al:No Durable Impact of COVID-19 on Intestinal Disease Activity in Subjects With IBD. Clin Gastroenterol Hepatol, 19:2312-2314.e3, 2021
 
25) Yoda T & Katsuyama H:Willingness to Receive COVID-19 Vaccination in Japan. Vaccines (Basel), 9:48, 2021
PubMed
26) Lev-Tzion R, et al:COVID-19 Vaccine Is Effective in Inflammatory Bowel Disease Patients and Is Not Associated With Disease Exacerbation. Clin Gastroenterol Hepatol, 20:e1263-e1282, 2022
PubMed
27) Kappelman MD, et al:Factors Affecting Initial Humoral Immune Response to SARSCoV-2 Vaccines Among Patients With Inflammatory Bowel Diseases. Am J Gastroenterol, 117:462-469, 2022
 
28) Alexander JL, et al:COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP):a multicentre, prospective, case-control study. Lancet Gastroenterol Hepatol, 7:1005-1015, 2022
 
29) Long MD, et al:Strong Response to SARS-CoV-2 Vaccine Additional Doses Among Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol, 20:1881-1883.e1, 2022
 

Advanced

P.213 掲載の参考文献
1) Ryan FJ, et al:Colonic microbiota is associated with inflammation and host epigenomic alterations in inflammatory bowel disease. Nat Commun, 11:1512, 2020
PubMed
2) Huang B, et al:Mucosal Profiling of Pediatric-Onset Colitis and IBD Reveals Common Pathogenics and Therapeutic Pathways. Cell, 179:1160-1176.e24, 2019
 
3) Corridoni D, et al:Single-cell atlas of colonic CD8(+) T cells in ulcerative colitis. Nat Med, 26:1480-1490, 2020
PubMed
4) Bossuyt P, et al:Automatic, computer-aided determination of endoscopic and histological inflammation in patients with mild to moderate ulcerative colitis based on red density. Gut, 69:1778-1786, 2020
PubMed

書評

最近チェックした商品履歴

Loading...